Pharmicell Co (XKRX:005690) Interest Expense : ₩-1,261 Mil (TTM As of Mar. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pharmicell Co's interest expense for the three months ended in Mar. 2024 was ₩ -29 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-1,261 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pharmicell Co's Operating Income for the three months ended in Mar. 2024 was ₩ -2,005 Mil. Pharmicell Co's Interest Expense for the three months ended in Mar. 2024 was ₩ -29 Mil. Pharmicell Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharmicell Co Interest Expense Historical Data

The historical data trend for Pharmicell Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Interest Expense Chart

Pharmicell Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-101.30

-84.89

-1,682.92

-746.20

-866.88

Pharmicell Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-154.51	-1,015.04	-217.01	-	-29.31

Pharmicell Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1,261 Mil.

Pharmicell Co (XKRX:005690) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharmicell Co's Interest Expense for the three months ended in Mar. 2024 was ₩-29 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₩-2,005 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₩368 Mil.

Pharmicell Co's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Pharmicell Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Pharmicell Co (XKRX:005690) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010

Website

http://www.pharmicell.com

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines